Transfusion support in patients with hematologic disease: Transfusions in special clinical circumstances.

[1]  Matthew J. Frigault,et al.  State of the art in CAR T cell therapy for CD19+ B cell malignancies. , 2020, The Journal of clinical investigation.

[2]  N. Kröger,et al.  One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT) , 2019, Blood.

[3]  D. Stroncek,et al.  Transfusion Support in Patients with Hematologic Disease: New and Novel Transfusion Modalities. , 2019, Seminars in hematology.

[4]  H. Goldschmidt,et al.  Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network , 2019, Haematologica.

[5]  L. Krishnamurti,et al.  Curative Therapies for Sickle Cell Disease , 2019, Ochsner Journal.

[6]  Flora Peyvandi,et al.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.

[7]  M. Dhodapkar,et al.  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance , 2018, Journal of Immunotherapy for Cancer.

[8]  D. Weatherall,et al.  Sickle cell disease , 2018, Nature Reviews Disease Primers.

[9]  G. Holländer,et al.  CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  S. Glynn,et al.  2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine , 2017, Transfusion.

[11]  M. DeBaun,et al.  Evolution of sickle cell disease from a life‐threatening disease of children to a chronic disease of adults: The last 40 years , 2016, American journal of hematology.